PMID- 7042092
OWN - NLM
STAT- MEDLINE
DCOM- 19820708
LR  - 20151119
IS  - 0361-5960 (Print)
IS  - 0361-5960 (Linking)
VI  - 66
IP  - 4
DP  - 1982 Apr
TI  - Intergroup Hodgkin's disease in children study of stages I and II: a preliminary 
      report.
PG  - 937-47
AB  - The intergroup study of involved-field (IF) radiotherapy, IF radiotherapy plus 
      MOPP chemotherapy, and extended-field (EF) radiotherapy for treatment of 
      Hodgkin's disease in children has assessed 305 patients. Of these, 279 were "not 
      ineligible" (no mediate cause for disqualification). Among 223 randomized 
      patients, 144 were evaluable, 131 had documentation of complete or partial 
      remission, 20 of the remitters relapsed, and two died. Among 62 nonrandomized 
      patients with favorable presentations (unilateral upper neck, unilateral 
      inguinal, or massive mediastinal disease), 29 had documented remission, two 
      relapsed, and none died. Length of initial disease control (LIDC) was used to 
      measure duration of response. LIDC was best in patients given IF plus MOPP, and 
      95% are disease free. EF was better than IF radiotherapy (P = 0.004). Of the 
      disease characteristics prognostic for response (stage, histologic subtype, and 
      presence of symptoms), only the last factor had a statistically significant 
      effect on LIDC (P = 0.004). Ninety-six percent of the patients survive. Using 
      criteria developed by the committee, 23% of the staging procedures reviewed were 
      nonevaluable and 28% of the radiotherapy treatments were nonevaluable. The 
      necessity for criteria for evaluation of staging and treatment is certain. Length 
      of followup is too short for correlations of treatment with significant late 
      effects and for relevant therapeutic recommendations.
FAU - Sullivan, M P
AU  - Sullivan MP
FAU - Fuller, L M
AU  - Fuller LM
FAU - Chen, T
AU  - Chen T
FAU - Fisher, R
AU  - Fisher R
FAU - Fryer, C
AU  - Fryer C
FAU - Gehan, E
AU  - Gehan E
FAU - Gilchrist, G S
AU  - Gilchrist GS
FAU - Hays, D
AU  - Hays D
FAU - Hanson, W
AU  - Hanson W
FAU - Heller, R
AU  - Heller R
FAU - Higgins, G
AU  - Higgins G
FAU - Jenkin, D
AU  - Jenkin D
FAU - Kung, F
AU  - Kung F
FAU - Sheehan, W
AU  - Sheehan W
FAU - Tefft, M
AU  - Tefft M
FAU - Ternberg, J
AU  - Ternberg J
FAU - Wharam, M
AU  - Wharam M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Cancer Treat Rep
JT  - Cancer treatment reports
JID - 7607107
RN  - 0 (Antineoplastic Agents)
RN  - 35S93Y190K (Procarbazine)
RN  - 50D9XSG0VR (Mechlorethamine)
RN  - 5J49Q6B70F (Vincristine)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Antineoplastic Agents/*administration & dosage
MH  - Child
MH  - Clinical Trials as Topic
MH  - Drug Therapy, Combination
MH  - Hodgkin Disease/*drug therapy/*radiotherapy
MH  - Humans
MH  - Mechlorethamine/administration & dosage
MH  - Prednisone/administration & dosage
MH  - Procarbazine/administration & dosage
MH  - Vincristine/administration & dosage
EDAT- 1982/04/01 00:00
MHDA- 1982/04/01 00:01
CRDT- 1982/04/01 00:00
PHST- 1982/04/01 00:00 [pubmed]
PHST- 1982/04/01 00:01 [medline]
PHST- 1982/04/01 00:00 [entrez]
PST - ppublish
SO  - Cancer Treat Rep. 1982 Apr;66(4):937-47.